Merck (MRK) Common Equity (2009 - 2026)

Merck has disclosed Common Equity across 18 years of filings, most recently posting $45.9 billion for Q1 2026.

• In Q1 2026, Common Equity fell 5.1% year-over-year to $45.9 billion; the TTM figure through Mar 2026 stood at $45.9 billion (down 5.1% YoY), while the FY2025 annual figure was $52.6 billion, up 13.44% from the prior year.
• Common Equity eased to $45.9 billion in Q1 2026, from $52.6 billion in the prior quarter.
• Over the last five years, Common Equity for MRK reached as high as $52.6 billion in Q4 2025 and fell as low as $37.6 billion in Q4 2023.
• The 5-year median for Common Equity is $44.6 billion (2024), against an average of $44.8 billion.
• Annual changes were most pronounced in 2022 — Common Equity surged 51.46% — and 2023, when it decreased 18.29%.
• A 5-year view of Common Equity shows it stood at $46.1 billion in 2022, then fell by 18.29% to $37.6 billion in 2023, then grew by 23.22% to $46.4 billion in 2024, then advanced by 13.44% to $52.6 billion in 2025, then retreated by 12.69% to $45.9 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $45.9 billion, $52.6 billion, and $51.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.